162 related articles for article (PubMed ID: 17462168)
1. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.
Meola M; Petrucci I; Barsotti G
Nephrol Dial Transplant; 2009 Mar; 24(3):982-9. PubMed ID: 19181759
[TBL] [Abstract][Full Text] [Related]
3. Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study.
Laurain E; Ayav C; Erpelding ML; Kessler M; Briançon S; Brunaud L; Frimat L
BMC Nephrol; 2014 Aug; 15():132. PubMed ID: 25123022
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study.
St Peter WL; Yusuf AA; Do T; Lowe KA; Liu J; Nieman KM; Bradbury BD; Collins AJ
BMC Nephrol; 2015 Mar; 16():41. PubMed ID: 25886282
[TBL] [Abstract][Full Text] [Related]
5. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Moe SM; Abdalla S; Chertow GM; Parfrey PS; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Dehmel B; Goodman WG; Drüeke TB;
J Am Soc Nephrol; 2015 Jun; 26(6):1466-75. PubMed ID: 25505257
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.
Evans M; Methven S; Gasparini A; Barany P; Birnie K; MacNeill S; May MT; Caskey FJ; Carrero JJ
Sci Rep; 2018 Feb; 8(1):2103. PubMed ID: 29391567
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Parathyroidectomy vs Medical Treatments for Secondary Hyperparathyroidism in Patients Undergoing Dialysis: A Meta-Analysis.
Song Z; Wu C; Wang R; Gillis A; Fazendin J; Lindeman B; Chen H
Endocr Pract; 2024 Jun; 30(6):569-576. PubMed ID: 38583772
[TBL] [Abstract][Full Text] [Related]
8. The Calcium-Sensing Receptor Gene Polymorphism rs1801725 and Calcium-Related Phenotypes in Hemodialysis Patients.
Grzegorzewska AE; Bednarski D; Świderska M; Mostowska A; Jagodziński PP
Kidney Blood Press Res; 2018; 43(3):719-734. PubMed ID: 29763933
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
[TBL] [Abstract][Full Text] [Related]
10. What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Moe SM; Thadhani R
Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):651-5. PubMed ID: 24100218
[TBL] [Abstract][Full Text] [Related]
11. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States.
Hall R; Platt A; Wilson J; Ephraim PL; Hwang AS; Chen A; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1603-1613. PubMed ID: 33046525
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain.
Villa G; Sánchez-Álvarez E; Cuervo J; Fernández-Ortiz L; Rebollo P; Ortega F
BMC Health Serv Res; 2012 Aug; 12():257. PubMed ID: 22897891
[TBL] [Abstract][Full Text] [Related]
13. Is brief advice in primary care a cost-effective way to promote physical activity?
Anokye NK; Lord J; Fox-Rushby J
Br J Sports Med; 2014 Feb; 48(3):202-6. PubMed ID: 24352807
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease.
Zhang W; Ren H; Liao Q; Wu J
Calcif Tissue Int; 2024 Apr; 114(4):368-376. PubMed ID: 38376758
[TBL] [Abstract][Full Text] [Related]
15. Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes: A cost-effectiveness analysis.
Padula WV; Chen YH; Santamaria N
Int Wound J; 2019 Dec; 16(6):1263-1272. PubMed ID: 31475434
[TBL] [Abstract][Full Text] [Related]
16. The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients.
Caria S; Cupisti A; Sau G; Bolasco P
BMC Nephrol; 2014 Oct; 15():172. PubMed ID: 25352299
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials.
Wakamatsu T; Yamamoto S; Matsuo K; Taniguchi M; Hamano T; Fukagawa M; Kazama JJ
J Bone Miner Metab; 2024 May; 42(3):316-325. PubMed ID: 38536478
[TBL] [Abstract][Full Text] [Related]
18. Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease.
Yang KC; Chen HH
Curr Alzheimer Res; 2016; 13(7):809-16. PubMed ID: 26825097
[TBL] [Abstract][Full Text] [Related]
19. A new paradigm for the treatment of secondary hyperparathyroidism.
de Francisco AL; Carrera F
NDT Plus; 2008 Jan; 1(Suppl 1):i24-i28. PubMed ID: 25983953
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension.
Taylor RS; Bentley A; Metcalfe K; Lobo MD; Kirtane AJ; Azizi M; Clark C; Murphy K; Boer JH; van Keep M; Ta AT; Barman NC; Schwab G; Akehurst R; Schmieder RE
Pharmacoecon Open; 2024 Jan; ():. PubMed ID: 38289517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
